Peptide Reference Desk
Tesofensine is not a peptide: why it still appears in peptide catalogs
Tesofensine is a chlorinated small-molecule monoamine reuptake inhibitor, not an amino-acid peptide. The classification changes identity testing and evidence review.
Catalog placement is not chemistry
Tesofensine is a synthetic chlorinated small molecule developed through CNS drug research. It contains no amino-acid sequence and is not a peptide. It appears in peptide catalogs because it overlaps with metabolic and weight-management search traffic—not because it belongs to the molecular class.
The analytical consequence
Sequence confirmation, peptide mapping and amino-acid analysis are irrelevant starting points. A qualified tesofensine method should address exact chemical form, stereochemistry, salt status, related synthesis impurities, degradation products and residual solvents.
A catalog taxonomy may help navigation; it should never overwrite the test article’s chemical identity.
Mechanism claims need active-metabolite context
Tesofensine is generally discussed as a monoamine reuptake inhibitor. Its metabolite NS2360 appears in pharmacology records and should be separated from the parent compound in bioanalysis. Assays that do not resolve parent and metabolite can misstate exposure.
How to write the evidence summary
Record development indication, trial phase, population, comparator, cardiovascular monitoring and discontinuation history. Do not use “research peptide” as a safety or regulatory category, and do not transfer GLP-1 evidence to tesofensine merely because both appear in weight-management searches.
Verify with primary records
Use the primary paper, current regulator label or lot-linked analytical file for the claim it supports. A search result is a route to evidence, not the evidence itself.